New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and other CD30-expressing peripheral T-cell lymphoma (PTCL).
This is the first FDA approved frontline treatment for patients with PTCL. Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL. ADC’s are targeted therapies designed to deliver a cell-killing agent to a protein, such as CD30, which is found on some types of lymphoma cells.
“Today’s approval represents a major advancement for the treatment of peripheral T-cell lymphoma (PTCL) and anaplastic large cell lymphoma (ALCL),” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “For a patient population with limited treatment options, the approval of a new therapy for frontline PTCL offers new hope; the Lymphoma Research Foundation commends the patients and investigators who support such research and advance science forward, so that we may improve outcomes for all lymphoma patients and, hopefully, ultimately move closer to finding a cure.”